R. Tandon, R. Belmaker, W. Gattaz, J. Lopez-ibor, . Jr et al., World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia, Schizophrenia Research, vol.100, issue.1-3, pp.1-320, 2008.
DOI : 10.1016/j.schres.2007.11.033

C. Correll, C. Rummel-kluge, C. Corves, J. Kane, and S. Leucht, Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials, Schizophrenia Bulletin, vol.35, issue.2, pp.443-457, 2009.
DOI : 10.1093/schbul/sbn018

C. Barbui, A. Signoretti, S. Mule, M. Boso, and A. Cipriani, Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull, pp.458-468, 2009.

M. Edlinger, A. Hausmann, G. Kemmler, M. Kurz, I. Kurzthaler et al., Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period, Schizophrenia Research, vol.77, issue.1, pp.25-34, 2005.
DOI : 10.1016/j.schres.2005.01.015

A. Ballerini, R. Boccalon, G. Boncompagni, M. Casacchia, F. Margari et al., Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (Psychiatric EmeRgency Study and EpidemiOlogy) survey, Annals of General Psychiatry, vol.6, issue.1, p.29, 2007.
DOI : 10.1186/1744-859X-6-29

D. Faries, H. Ascher-svanum, B. Zhu, C. Correll, and J. Kane, Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics, BMC Psychiatry, vol.31, issue.1, p.26, 2005.
DOI : 10.1097/01.jcp.0000117422.05703.ae

A. Jaffe and J. Levine, Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and drug safety, pp.41-48, 2003.

E. Johnsen, G. Svingen, and H. Jorgensen, Practice regarding antipsychotic therapy: A cross-sectional survey in two Norwegian hospitals, Nordic Journal of Psychiatry, vol.55, issue.4, pp.313-317, 2004.
DOI : 10.1080/08039480410005837

R. Kroken, E. Johnsen, T. Ruud, T. Wentzel-larsen, and H. Jorgensen, Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study, BMC Psychiatry, vol.112, issue.1, p.24, 2009.
DOI : 10.1111/j.1600-0447.2005.00547.x

T. Gilmer, C. Dolder, J. Lacro, D. Folsom, L. Lindamer et al., Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia, American Journal of Psychiatry, vol.161, issue.4, pp.692-699, 2004.
DOI : 10.1176/appi.ajp.161.4.692

M. Joukamaa, M. Heliovaara, P. Knekt, A. Aromaa, R. Raitasalo et al., Schizophrenia, neuroleptic medication and mortality, The British Journal of Psychiatry, vol.188, issue.2, pp.122-127, 2006.
DOI : 10.1192/bjp.188.2.122

L. Baandrup, C. Gasse, V. Jensen, B. Glenthoj, M. Nordentoft et al., Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia, The Journal of Clinical Psychiatry, vol.71, issue.02, pp.71103-108, 2010.
DOI : 10.4088/JCP.08m04818yel

M. Morgan, P. Scully, H. Youssef, A. Kinsella, J. Owens et al., Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland, Psychiatry Research, vol.117, issue.2, pp.127-135, 2003.
DOI : 10.1016/S0165-1781(03)00002-7

J. Tiihonen, J. Lonnqvist, K. Wahlbeck, T. Klaukka, L. Niskanen et al., 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), The Lancet, vol.374, issue.9690, pp.374620-627, 2009.
DOI : 10.1016/S0140-6736(09)60742-X

J. De-leon, Beyond the "Hype" on the Association Between Metabolic Syndrome and Atypical Antipsychotics, Journal of Clinical Psychopharmacology, vol.28, issue.2, pp.1471-244, 2011.
DOI : 10.1097/JCP.0b013e318166f533

D. Agostino and R. Jr, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, pp.2265-2281, 1998.

P. Bebbington, M. Angermeyer, J. Azorin, T. Brugha, R. Kilian et al., The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Social psychiatry and psychiatric epidemiology, pp.40707-717, 2005.

D. Heider, M. Angermeyer, I. Winkler, G. Schomerus, P. Bebbington et al., A prospective study of Quality of life in schizophrenia in three European countries, Schizophrenia Research, vol.93, issue.1-3, pp.1-3194, 2007.
DOI : 10.1016/j.schres.2007.03.005

D. Heider, S. Bernert, H. Konig, H. Matschinger, T. Hogh et al., Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom -findings from the European Schizophrenia Cohort (EuroSC) Eur Psychiatry, pp.216-224, 2009.

S. Marwaha, S. Johnson, P. Bebbington, M. Angermeyer, T. Brugha et al., Correlates of Subjective Quality of Life in People With Schizophrenia, The Journal of Nervous and Mental Disease, vol.196, issue.2, pp.87-94, 2008.
DOI : 10.1097/NMD.0b013e318162aa9c

S. Marwaha, S. Johnson, P. Bebbington, M. Angermeyer, T. Brugha et al., Predictors of employment status change over 2 years in people with schizophrenia living in Europe. Epidemiologia e psichiatria sociale, pp.344-351, 2009.

C. Roick, D. Heider, P. Bebbington, M. Angermeyer, J. Azorin et al., Burden on caregivers of people with schizophrenia: comparison between Germany and Britain, The British Journal of Psychiatry, vol.190, issue.4, pp.333-338, 2007.
DOI : 10.1192/bjp.bp.106.025353

G. Schomerus, D. Heider, M. Angermeyer, P. Bebbington, J. Azorin et al., Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC) Social psychiatry and psychiatric epidemiology, pp.42617-622, 2007.

G. Schomerus, D. Heider, M. Angermeyer, P. Bebbington, J. Azorin et al., Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC), Psychological Medicine, vol.188, issue.04, pp.591-597, 2008.
DOI : 10.1093/schbul/sbi060

H. Verdoux, The current state of adult mental health care in France, European Archives of Psychiatry and Clinical Neuroscience, vol.183, issue.suppl 410, pp.64-70, 2007.
DOI : 10.1007/s00406-006-0693-z

S. Kay, L. Opler, and A. Fiszbein, Significance of positive and negative syndromes in chronic schizophrenia, The British Journal of Psychiatry, vol.149, issue.4, pp.439-448, 1986.
DOI : 10.1192/bjp.149.4.439

C. Lancon, R. G. Llorca, P. Auquier, and P. , Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS), Acta Psychiatrica Scandinavica, vol.158, issue.3, pp.237-243, 1999.
DOI : 10.1016/0920-9964(90)90005-R

J. Endicott, R. Spitzer, J. Fleiss, and J. Cohen, The Global Assessment Scale, Archives of General Psychiatry, vol.33, issue.6, pp.766-771, 1976.
DOI : 10.1001/archpsyc.1976.01770060086012

B. Dausch, D. Miklowitz, and J. Richards, Global Assessment of Relational Functioning Scale (GARF): II. Reliability and Validity in a Sample of Families of Bipolar Patients, Family Process, vol.129, issue.2, pp.175-189, 1996.
DOI : 10.1111/j.1545-5300.1989.00169.x

H. Goldman, A. Skodol, and T. Lave, Revising axis V for DSM-IV: a review of measures of social functioning, Am J Psychiatry, vol.149, issue.9, pp.1148-1156, 1992.

D. Addington, J. Addington, and E. Maticka-tyndale, Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry, vol.22, pp.39-44, 1993.

C. Lancon, P. Auquier, R. G. Toumi, M. Addington, and D. , Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale, Psychiatry Research, vol.89, issue.2, pp.123-132, 1999.
DOI : 10.1016/S0165-1781(99)00097-9

S. Simpson and R. Angus, A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS, Acta Psychiatrica Scandinavica, vol.45, issue.S212, pp.11-19, 1970.
DOI : 10.1111/j.1600-0447.1970.tb02066.x

T. Barnes, A rating scale for drug-induced akathisia, The British Journal of Psychiatry, vol.154, issue.5, pp.672-676, 1989.
DOI : 10.1192/bjp.154.5.672

R. Lane, W. Glazer, T. Hansen, W. Berman, and S. Kramer, Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. The Journal of nervous and mental disease, pp.353-357, 1985.

P. Weiden, B. Rapkin, T. Mott, A. Zygmunt, D. Goldman et al., Rating of Medication Influences (ROMI) Scale in Schizophrenia, Schizophrenia Bulletin, vol.20, issue.2, pp.297-310, 1994.
DOI : 10.1093/schbul/20.2.297

A. Leplege, E. Ecosse, A. Verdier, and T. Perneger, The French SF-36 Health Survey, Journal of Clinical Epidemiology, vol.51, issue.11, pp.511013-1023, 1998.
DOI : 10.1016/S0895-4356(98)00093-6

J. Ware, . Jr, and C. Sherbourne, The MOS 36-ltem Short-Form Health Survey (SF-36), Medical Care, vol.30, issue.6, pp.473-483, 1992.
DOI : 10.1097/00005650-199206000-00002

M. Lader, What is relapse in schizophrenia?, International Clinical Psychopharmacology, vol.9, issue.5, pp.5-9, 1995.
DOI : 10.1097/00004850-199501005-00002

S. Leucht, S. Heres, J. Hamann, and J. Kane, Methodological Issues in Current Antipsychotic Drug Trials, Schizophrenia Bulletin, vol.34, issue.2, pp.275-285, 2008.
DOI : 10.1093/schbul/sbm159

P. Austin, P. Grootendorst, S. Normand, and G. Anderson, Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study, Statistics in Medicine, vol.137, issue.4, pp.754-768, 2007.
DOI : 10.1002/sim.2618

C. Correll, A. Frederickson, J. Kane, and P. Manu, Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia research, pp.91-100, 2007.

M. Cepeda, R. Boston, J. Farrar, and B. Strom, Comparison of Logistic Regression versus Propensity Score When the Number of Events Is Low and There Are Multiple Confounders, American Journal of Epidemiology, vol.158, issue.3, pp.280-287, 2003.
DOI : 10.1093/aje/kwg115

T. Rajji, Z. Ismail, and B. Mulsant, Age at onset and cognition in schizophrenia: meta-analysis, The British Journal of Psychiatry, vol.195, issue.4, pp.286-293, 2009.
DOI : 10.1192/bjp.bp.108.060723

F. Centorrino, K. Fogarty, G. Sani, P. Salvatore, S. Cincotta et al., Use of combinations of antipsychotics: McLean Hospital inpatients, 2002, Human Psychopharmacology: Clinical and Experimental, vol.64, issue.7, pp.485-492, 2002.
DOI : 10.1002/hup.719

J. Kreyenbuhl, M. Valenstein, J. Mccarthy, D. Ganoczy, and F. Blow, Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns, Psychiatric Services, vol.58, issue.4, pp.489-495, 2007.
DOI : 10.1176/ps.2007.58.4.489

M. Sernyak and R. Rosenheck, Clinicians' reasons for antipsychotic coprescribing. The Journal of clinical psychiatry, pp.1597-1600, 2004.

A. Tapp, A. Wood, L. Secrest, J. Erdmann, L. Cubberley et al., Combination Antipsychotic Therapy in Clinical Practice, Psychiatric Services, vol.54, issue.1, pp.55-59, 2003.
DOI : 10.1176/appi.ps.54.1.55

R. Mojtabai and M. Olfson, National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry, Archives of General Psychiatry, vol.67, issue.1, pp.26-36
DOI : 10.1001/archgenpsychiatry.2009.175

R. Conley, H. Ascher-svanum, B. Zhu, D. Faries, and B. Kinon, The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophrenia research, pp.1-3186, 2007.

L. Citrome, A. Jaffe, and J. Levine, Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients, American Journal of Psychiatry, vol.162, issue.3, pp.631-632, 2005.
DOI : 10.1176/appi.ajp.162.3.631

R. Procyshyn, N. Kennedy, G. Tse, and B. Thompson, Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution, The Canadian Journal of Psychiatry, vol.133, issue.4, pp.334-339, 2001.
DOI : 10.1001/archpsyc.1988.01800330013001

D. Velligan, P. Weiden, M. Sajatovic, J. Scott, D. Carpenter et al., The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The Journal of clinical psychiatry, pp.1-46, 2009.

D. Rubin, Estimating Causal Effects from Large Data Sets Using Propensity Scores, Annals of Internal Medicine, vol.127, issue.8_Part_2, pp.757-763, 1997.
DOI : 10.7326/0003-4819-127-8_Part_2-199710151-00064